[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f9DV40fyoloaZS-OZ-dNRJCTG1nvJuVUYvuWxl_JDu14":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":83,"rows":90},"Unity Health Toronto",[4],434,false,65,24,263889,18,348,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Major Depressive Disorder",12,{"name":18,"count":19},"Diabetes",8,{"name":21,"count":19},"HIV",{"name":23,"count":24},"Cardiovascular Diseases",7,{"name":26,"count":24},"Healthy",{"name":28,"count":24},"Obesity",{"name":30,"count":24},"Suicide",{"name":32,"count":24},"Respiratory Insufficiency",[34,39,44,49,54,59,64,69,74,78],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05614349","Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings","2025-04-28","Paxlovid",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05523869","Intravitreal Topotecan in the Repair of Rhegmatogenous Retinal Detachment with Proliferative Vitreoretinopathy","2026-02","Intravitreal topotecan",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06843174","Perioperative Rectal Methadone in Spine Surgery","2026-07","Rectal Methadone administer during spinal surgery",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06809998","COntralateral CorticoSTeroid Injection in Total Knee Arthroplasty","2026-07-30","Corticosteroid Injection - 80mg methylprednisolone (total volume 2ml) with 6 mL of 1% Bupivacaine without epinephrine (Total Volume 8 mL).",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT06731335","Psilocybin for Enhanced Analgesia in Chronic nEuropathic PAIN","2026-08","Psilocybin",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06205095","A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWD","2026-09","Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT06495294","SWiFT Canada (Study of Whole Blood in Frontline Trauma)","2026-12","Whole Blood",{"nctId":70,"briefTitle":71,"date":72,"intervention":73},"NCT06163625","The Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression","2026-12-31","Saliva Samples",{"nctId":75,"briefTitle":76,"date":77,"intervention":58},"NCT06386003","Psilocybin-Assisted Cognitive Processing Therapy for Chronic PTSD","2027-01",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT05713630","The Use of Tranexamic Acid in the Treatment of Symptomatic Subdural Hematoma","2027-03-30","Tranexamic acid",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,122,152,175,199,217,246,267,289,322,354,379,397,422,447,465,485,507,525,575,613,648,685,712,730,757,782,808,833,858,882,900,924,949,975,993,1014,1039,1063,1095,1120,1146,1173,1200,1224,1250,1274,1301,1319,1342,1366,1384,1402,1428,1453,1482,1500,1524,1550,1574,1603,1621,1644,1666,1690,1714,1739,1766,1784,1808,1833,1857,1880,1904,1928,1953,1981,2005,2031,2049,2073,2091,2115,2141,2163,2187,2214,2232,2257,2280,2304,2332,2358,2381],{"intervention":92,"totalTrials":93,"cells":94},"Semaglutide Pen",1,{"EARLY_PHASE1":95,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":104,"NA":120},{"trials":96,"activeCount":97},[],0,{"trials":99,"activeCount":97},[],{"trials":101,"activeCount":97},[],{"trials":103,"activeCount":97},[],{"trials":105,"activeCount":93,"soonestReadout":111},[106],{"nctId":107,"briefTitle":108,"status":109,"phases":110,"primaryCompletion":111,"completion":112,"start":113,"enrollment":114,"conditions":115,"interventions":119},"NCT07017270","Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis","NOT_YET_RECRUITING",[88],"2027-07","2027-09","2025-07",100,[116,18,117,118],"Kidney Disease, Chronic","Dialysis","End Stage Kidney Disease (ESRD)",[92],{"trials":121,"activeCount":97},[],{"intervention":123,"totalTrials":93,"cells":124},"Epinephrine",{"EARLY_PHASE1":125,"PHASE1":127,"PHASE2":129,"PHASE3":131,"PHASE4":133,"NA":150},{"trials":126,"activeCount":97},[],{"trials":128,"activeCount":97},[],{"trials":130,"activeCount":97},[],{"trials":132,"activeCount":97},[],{"trials":134,"activeCount":93,"soonestReadout":140},[135],{"nctId":136,"briefTitle":137,"status":138,"phases":139,"primaryCompletion":140,"completion":141,"start":142,"enrollment":143,"conditions":144,"interventions":149},"NCT03826524","Epinephrine Dose: Optimal Versus Standard Evaluation Trial","RECRUITING",[88],"2027-12","2028-12","2023-05-24",3790,[145,146,147,148],"Cardiac Arrest, Out-Of-Hospital","Sudden Cardiac Arrest","Ventricular Fibrillation","Ventricular Tachycardia-Pulseless",[123],{"trials":151,"activeCount":97},[],{"intervention":48,"totalTrials":93,"cells":153},{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":160,"PHASE4":162,"NA":173},{"trials":155,"activeCount":97},[],{"trials":157,"activeCount":97},[],{"trials":159,"activeCount":97},[],{"trials":161,"activeCount":97},[],{"trials":163,"activeCount":93,"soonestReadout":47},[164],{"nctId":45,"briefTitle":46,"status":138,"phases":165,"primaryCompletion":47,"completion":57,"start":166,"enrollment":167,"conditions":168,"interventions":172},[88],"2025-02-19",40,[169,170,171],"Spinal Surgery","Post-operative Care","Post-operative Pain Management",[48],{"trials":174,"activeCount":97},[],{"intervention":38,"totalTrials":93,"cells":176},{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":183,"PHASE4":195,"NA":197},{"trials":178,"activeCount":97},[],{"trials":180,"activeCount":97},[],{"trials":182,"activeCount":97},[],{"trials":184,"activeCount":93,"soonestReadout":37},[185],{"nctId":35,"briefTitle":36,"status":186,"phases":187,"primaryCompletion":37,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"ACTIVE_NOT_RECRUITING",[87],"2025-06-28","2023-01-16",797,[192],"COVID-19",[38,194],"Antioxidant",{"trials":196,"activeCount":97},[],{"trials":198,"activeCount":97},[],{"intervention":194,"totalTrials":93,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":213,"NA":215},{"trials":202,"activeCount":97},[],{"trials":204,"activeCount":97},[],{"trials":206,"activeCount":97},[],{"trials":208,"activeCount":93,"soonestReadout":37},[209],{"nctId":35,"briefTitle":36,"status":186,"phases":210,"primaryCompletion":37,"completion":188,"start":189,"enrollment":190,"conditions":211,"interventions":212},[87],[192],[38,194],{"trials":214,"activeCount":97},[],{"trials":216,"activeCount":97},[],{"intervention":218,"totalTrials":93,"cells":219},"Baloxavir",{"EARLY_PHASE1":220,"PHASE1":222,"PHASE2":224,"PHASE3":226,"PHASE4":242,"NA":244},{"trials":221,"activeCount":97},[],{"trials":223,"activeCount":97},[],{"trials":225,"activeCount":97},[],{"trials":227,"activeCount":93,"soonestReadout":232},[228],{"nctId":229,"briefTitle":230,"status":109,"phases":231,"primaryCompletion":232,"completion":233,"start":234,"enrollment":235,"conditions":236,"interventions":241},"NCT07314905","Adaptive Platform Trial of Treatments for Respiratory Infections in Community Settings (TreatResp)",[87],"2027-03-31","2027-04-24","2026-01-02",264,[237,238,239,240],"Influenza A","Influenza B","SAR-CoV-2","Acute Respiratory Infections (ARIs)",[218],{"trials":243,"activeCount":97},[],{"trials":245,"activeCount":97},[],{"intervention":63,"totalTrials":93,"cells":247},{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":263,"NA":265},{"trials":249,"activeCount":97},[],{"trials":251,"activeCount":97},[],{"trials":253,"activeCount":97},[],{"trials":255,"activeCount":93,"soonestReadout":62},[256],{"nctId":60,"briefTitle":61,"status":138,"phases":257,"primaryCompletion":62,"completion":62,"start":258,"enrollment":259,"conditions":260,"interventions":262},[87],"2024-10-21",20,[261],"Von Willebrand Diseases",[63],{"trials":264,"activeCount":97},[],{"trials":266,"activeCount":97},[],{"intervention":82,"totalTrials":93,"cells":268},{"EARLY_PHASE1":269,"PHASE1":271,"PHASE2":273,"PHASE3":275,"PHASE4":285,"NA":287},{"trials":270,"activeCount":97},[],{"trials":272,"activeCount":97},[],{"trials":274,"activeCount":97},[],{"trials":276,"activeCount":93,"soonestReadout":81},[277],{"nctId":79,"briefTitle":80,"status":138,"phases":278,"primaryCompletion":81,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":284},[87],"2030-12-31","2026-05-20",130,[283],"Subdural Hematoma",[82],{"trials":286,"activeCount":97},[],{"trials":288,"activeCount":97},[],{"intervention":58,"totalTrials":290,"cells":291},2,{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":316,"PHASE4":318,"NA":320},{"trials":293,"activeCount":97},[],{"trials":295,"activeCount":97},[],{"trials":297,"activeCount":290,"soonestReadout":57},[298,307],{"nctId":75,"briefTitle":76,"status":109,"phases":299,"primaryCompletion":77,"completion":77,"start":300,"enrollment":301,"conditions":302,"interventions":306},[86],"2026-05",15,[303,304,305],"Post Traumatic Stress Disorder","PTSD","Chronic PTSD",[58],{"nctId":55,"briefTitle":56,"status":138,"phases":308,"primaryCompletion":57,"completion":67,"start":309,"enrollment":310,"conditions":311,"interventions":314},[86],"2025-03-05",30,[312,313],"Chronic Neuropathic Pain","Pain Management",[58,315],"Active Placebo",{"trials":317,"activeCount":97},[],{"trials":319,"activeCount":97},[],{"trials":321,"activeCount":97},[],{"intervention":43,"totalTrials":290,"cells":323},{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":348,"PHASE4":350,"NA":352},{"trials":325,"activeCount":97},[],{"trials":327,"activeCount":97},[],{"trials":329,"activeCount":290,"soonestReadout":42},[330,341],{"nctId":331,"briefTitle":332,"status":109,"phases":333,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":340},"NCT06818721","Intravitreal Topotecan for Prevention or Treatment of Proliferative Vitreoretinopathy in Retinal Detachment",[86],"2027-04","2025-03",394,[338,339],"Retinal Detachment Rhegmatogenous","Proliferative Vitreoretinopathy",[43],{"nctId":40,"briefTitle":41,"status":138,"phases":342,"primaryCompletion":42,"completion":42,"start":343,"enrollment":344,"conditions":345,"interventions":347},[86],"2023-02-23",50,[346],"Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment",[43],{"trials":349,"activeCount":97},[],{"trials":351,"activeCount":97},[],{"trials":353,"activeCount":97},[],{"intervention":355,"totalTrials":93,"cells":356},"3,4-Methylenedioxymethamphetamine",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":373,"PHASE4":375,"NA":377},{"trials":358,"activeCount":97},[],{"trials":360,"activeCount":97},[],{"trials":362,"activeCount":93,"soonestReadout":367},[363],{"nctId":364,"briefTitle":365,"status":138,"phases":366,"primaryCompletion":367,"completion":368,"start":369,"enrollment":167,"conditions":370,"interventions":371},"NCT07301632","Ecstasy to Alleviate SEvere Chronic Neuropathic Pain Trial",[86],"2027-12-01","2028-12-01","2026-01-30",[312],[355,372],"Methylphenidate",{"trials":374,"activeCount":97},[],{"trials":376,"activeCount":97},[],{"trials":378,"activeCount":97},[],{"intervention":372,"totalTrials":93,"cells":380},{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":391,"PHASE4":393,"NA":395},{"trials":382,"activeCount":97},[],{"trials":384,"activeCount":97},[],{"trials":386,"activeCount":93,"soonestReadout":367},[387],{"nctId":364,"briefTitle":365,"status":138,"phases":388,"primaryCompletion":367,"completion":368,"start":369,"enrollment":167,"conditions":389,"interventions":390},[86],[312],[355,372],{"trials":392,"activeCount":97},[],{"trials":394,"activeCount":97},[],{"trials":396,"activeCount":97},[],{"intervention":53,"totalTrials":93,"cells":398},{"EARLY_PHASE1":399,"PHASE1":401,"PHASE2":403,"PHASE3":416,"PHASE4":418,"NA":420},{"trials":400,"activeCount":97},[],{"trials":402,"activeCount":97},[],{"trials":404,"activeCount":93,"soonestReadout":52},[405],{"nctId":50,"briefTitle":51,"status":138,"phases":406,"primaryCompletion":52,"completion":407,"start":408,"enrollment":409,"conditions":410,"interventions":415},[85,86],"2027-07-30","2025-01-24",60,[411,412,413,414],"Total Knee Anthroplasty","Osteoarthritis(Primary)","Osteoarthritis (OA) of the Knee","Bilateral Knee Osteoarthritis",[53],{"trials":417,"activeCount":97},[],{"trials":419,"activeCount":97},[],{"trials":421,"activeCount":97},[],{"intervention":423,"totalTrials":93,"cells":424},"Lemborexant",{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":441,"PHASE4":443,"NA":445},{"trials":426,"activeCount":97},[],{"trials":428,"activeCount":97},[],{"trials":430,"activeCount":93,"soonestReadout":140},[431],{"nctId":432,"briefTitle":433,"status":138,"phases":434,"primaryCompletion":140,"completion":435,"start":436,"enrollment":310,"conditions":437,"interventions":440},"NCT06843187","Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)",[86],"2028-04","2024-09-25",[438,439],"Major Depressive Disorder(MDD)","Insomnia Comorbid to Psychiatric Disorder",[423],{"trials":442,"activeCount":97},[],{"trials":444,"activeCount":97},[],{"trials":446,"activeCount":97},[],{"intervention":315,"totalTrials":93,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":459,"PHASE4":461,"NA":463},{"trials":450,"activeCount":97},[],{"trials":452,"activeCount":97},[],{"trials":454,"activeCount":93,"soonestReadout":57},[455],{"nctId":55,"briefTitle":56,"status":138,"phases":456,"primaryCompletion":57,"completion":67,"start":309,"enrollment":310,"conditions":457,"interventions":458},[86],[312,313],[58,315],{"trials":460,"activeCount":97},[],{"trials":462,"activeCount":97},[],{"trials":464,"activeCount":97},[],{"intervention":73,"totalTrials":93,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":471,"PHASE3":473,"PHASE4":475,"NA":477},{"trials":468,"activeCount":97},[],{"trials":470,"activeCount":97},[],{"trials":472,"activeCount":97},[],{"trials":474,"activeCount":97},[],{"trials":476,"activeCount":97},[],{"trials":478,"activeCount":93,"soonestReadout":72},[479],{"nctId":70,"briefTitle":71,"status":138,"phases":480,"primaryCompletion":72,"completion":72,"start":481,"enrollment":344,"conditions":482,"interventions":484},[89],"2025-01",[15,483],"Treatment Resistant Depression",[73],{"intervention":68,"totalTrials":93,"cells":486},{"EARLY_PHASE1":487,"PHASE1":489,"PHASE2":491,"PHASE3":493,"PHASE4":495,"NA":497},{"trials":488,"activeCount":97},[],{"trials":490,"activeCount":97},[],{"trials":492,"activeCount":97},[],{"trials":494,"activeCount":97},[],{"trials":496,"activeCount":97},[],{"trials":498,"activeCount":93,"soonestReadout":67},[499],{"nctId":65,"briefTitle":66,"status":138,"phases":500,"primaryCompletion":67,"completion":501,"start":502,"enrollment":409,"conditions":503,"interventions":505},[89],"2027-03","2024-12-16",[504],"Trauma",[68,506],"RBC + plasma",{"intervention":506,"totalTrials":93,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":519},{"trials":510,"activeCount":97},[],{"trials":512,"activeCount":97},[],{"trials":514,"activeCount":97},[],{"trials":516,"activeCount":97},[],{"trials":518,"activeCount":97},[],{"trials":520,"activeCount":93,"soonestReadout":67},[521],{"nctId":65,"briefTitle":66,"status":138,"phases":522,"primaryCompletion":67,"completion":501,"start":502,"enrollment":409,"conditions":523,"interventions":524},[89],[504],[68,506],{"intervention":526,"totalTrials":527,"cells":528},"aflibercept",3,{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":533,"PHASE3":535,"PHASE4":537,"NA":573},{"trials":530,"activeCount":97},[],{"trials":532,"activeCount":97},[],{"trials":534,"activeCount":97},[],{"trials":536,"activeCount":97},[],{"trials":538,"activeCount":97},[539,551,563],{"nctId":540,"briefTitle":541,"status":542,"phases":543,"primaryCompletion":544,"completion":544,"start":545,"enrollment":546,"conditions":547,"interventions":549},"NCT02002377","Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab Injections","TERMINATED",[88],"2017-02-21","2014-04-17",23,[548],"Age Related Macular Degeneration",[550],"Aflibercept",{"nctId":552,"briefTitle":553,"status":554,"phases":555,"primaryCompletion":556,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":562},"NCT02441907","Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema","COMPLETED",[88],"2018-08","2019-09","2015-08",16,[561],"Diabetic Macular Edema",[526],{"nctId":564,"briefTitle":565,"status":566,"phases":567,"primaryCompletion":568,"completion":569,"start":570,"enrollment":344,"conditions":571,"interventions":572},"NCT02651168","Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study","UNKNOWN",[88],"2018-03","2018-06","2016-03",[561],[526],{"trials":574,"activeCount":97},[],{"intervention":576,"totalTrials":290,"cells":577},"Normal Saline",{"EARLY_PHASE1":578,"PHASE1":580,"PHASE2":582,"PHASE3":584,"PHASE4":598,"NA":611},{"trials":579,"activeCount":97},[],{"trials":581,"activeCount":97},[],{"trials":583,"activeCount":97},[],{"trials":585,"activeCount":97},[586],{"nctId":587,"briefTitle":588,"status":554,"phases":589,"primaryCompletion":590,"completion":591,"start":592,"enrollment":593,"conditions":594,"interventions":596},"NCT00878631","Feasibility Trial of Traumatic Brain Injured Patients Randomized in the Prehospital Setting to Either Hypertonic Saline and Dextran Versus Normal Saline",[86,87],"2006-01","2008-12","2004-09",113,[595],"Brain Injuries",[597,576],"hypertonic saline mixed with dextran",{"trials":599,"activeCount":97},[600],{"nctId":601,"briefTitle":602,"status":554,"phases":603,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":608,"interventions":609},"NCT04727229","Stellate Ganglion Block for Major Depressive Disorder.",[88],"2022-02-10","2022-03-10","2021-09-23",10,[483,15],[610,576],"Bupivacaine Hydrochloride",{"trials":612,"activeCount":97},[],{"intervention":614,"totalTrials":290,"cells":615},"Empagliflozin",{"EARLY_PHASE1":616,"PHASE1":618,"PHASE2":620,"PHASE3":622,"PHASE4":624,"NA":646},{"trials":617,"activeCount":97},[],{"trials":619,"activeCount":97},[],{"trials":621,"activeCount":97},[],{"trials":623,"activeCount":97},[],{"trials":625,"activeCount":97},[626,636],{"nctId":627,"briefTitle":628,"status":554,"phases":629,"primaryCompletion":630,"completion":630,"start":631,"enrollment":632,"conditions":633,"interventions":635},"NCT04461041","Empagliflozin and Cardiac Remodelling in People Without Diabetes",[88],"2022-07-31","2021-04-01",169,[23,634],"Left Ventricular Hypertrophy",[614],{"nctId":637,"briefTitle":638,"status":566,"phases":639,"primaryCompletion":640,"completion":640,"start":641,"enrollment":642,"conditions":643,"interventions":645},"NCT02998970","Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 Diabetes",[88],"2018-09","2017-01",97,[18,644],"Cardiovascular Disease",[614],{"trials":647,"activeCount":97},[],{"intervention":649,"totalTrials":290,"cells":650},"Ticagrelor",{"EARLY_PHASE1":651,"PHASE1":653,"PHASE2":655,"PHASE3":657,"PHASE4":671,"NA":683},{"trials":652,"activeCount":97},[],{"trials":654,"activeCount":97},[],{"trials":656,"activeCount":97},[],{"trials":658,"activeCount":97},[659],{"nctId":660,"briefTitle":661,"status":554,"phases":662,"primaryCompletion":663,"completion":664,"start":665,"enrollment":666,"conditions":667,"interventions":669},"NCT01930591","Ticagrelor for PCI Post Thrombolysis",[87],"2016-10","2016-11","2014-05",140,[668],"Acute Myocardial Infarction",[649,670],"Clopidogrel",{"trials":672,"activeCount":97},[673],{"nctId":674,"briefTitle":675,"status":566,"phases":676,"primaryCompletion":677,"completion":677,"start":678,"enrollment":679,"conditions":680,"interventions":682},"NCT02627521","Optimizing Timing of CABG in Patients Presenting With ACS and Treated With Ticagrelor",[88],"2017-08","2015-07",260,[681],"Coronary Artery Disease",[649],{"trials":684,"activeCount":97},[],{"intervention":686,"totalTrials":93,"cells":687},"Pregabalin",{"EARLY_PHASE1":688,"PHASE1":690,"PHASE2":692,"PHASE3":694,"PHASE4":696,"NA":710},{"trials":689,"activeCount":97},[],{"trials":691,"activeCount":97},[],{"trials":693,"activeCount":97},[],{"trials":695,"activeCount":97},[],{"trials":697,"activeCount":97},[698],{"nctId":699,"briefTitle":700,"status":701,"phases":702,"primaryCompletion":703,"completion":703,"start":704,"enrollment":97,"conditions":705,"interventions":708},"NCT01591980","Effects of Perioperative Pregabalin for Post-Craniotomy Pain","WITHDRAWN",[88],"2014-08","2013-08",[706,707],"Chronic Postoperative Pain","Headache",[686,709],"pregabalin",{"trials":711,"activeCount":97},[],{"intervention":610,"totalTrials":93,"cells":713},{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":720,"PHASE4":722,"NA":728},{"trials":715,"activeCount":97},[],{"trials":717,"activeCount":97},[],{"trials":719,"activeCount":97},[],{"trials":721,"activeCount":97},[],{"trials":723,"activeCount":97},[724],{"nctId":601,"briefTitle":602,"status":554,"phases":725,"primaryCompletion":604,"completion":605,"start":606,"enrollment":607,"conditions":726,"interventions":727},[88],[483,15],[610,576],{"trials":729,"activeCount":97},[],{"intervention":731,"totalTrials":93,"cells":732},"Evolocumab",{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":741,"NA":755},{"trials":734,"activeCount":97},[],{"trials":736,"activeCount":97},[],{"trials":738,"activeCount":97},[],{"trials":740,"activeCount":97},[],{"trials":742,"activeCount":97},[743],{"nctId":744,"briefTitle":745,"status":554,"phases":746,"primaryCompletion":747,"completion":747,"start":748,"enrollment":749,"conditions":750,"interventions":754},"NCT03900026","Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery",[88],"2025-01-30","2019-05-30",782,[751,752,753],"Coronary Artery Bypass Graft Surgery","Atherosclerosis","Vein Occlusion",[731],{"trials":756,"activeCount":97},[],{"intervention":758,"totalTrials":93,"cells":759},"Asenapine",{"EARLY_PHASE1":760,"PHASE1":762,"PHASE2":764,"PHASE3":766,"PHASE4":768,"NA":780},{"trials":761,"activeCount":97},[],{"trials":763,"activeCount":97},[],{"trials":765,"activeCount":97},[],{"trials":767,"activeCount":97},[],{"trials":769,"activeCount":97},[770],{"nctId":771,"briefTitle":772,"status":554,"phases":773,"primaryCompletion":774,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":779},"NCT01400113","Treating Acutely Agitated Patients With Asenapine Sublingual Tablets",[88],"2012-12","2012-04",120,[778],"Agitation",[758],{"trials":781,"activeCount":97},[],{"intervention":783,"totalTrials":93,"cells":784},"Intravitreal aflibercept",{"EARLY_PHASE1":785,"PHASE1":787,"PHASE2":789,"PHASE3":791,"PHASE4":793,"NA":806},{"trials":786,"activeCount":97},[],{"trials":788,"activeCount":97},[],{"trials":790,"activeCount":97},[],{"trials":792,"activeCount":97},[],{"trials":794,"activeCount":97},[795],{"nctId":796,"briefTitle":797,"status":566,"phases":798,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":802,"interventions":805},"NCT03056079","Cytokine and Visual Outcome Variations in Eyes Receiving Aflibercept",[88],"2024-02-28","2017-02-28",168,[548,561,803,804],"Retinal Vein Occlusion","Macular Edema",[783],{"trials":807,"activeCount":97},[],{"intervention":809,"totalTrials":93,"cells":810},"Zoloft",{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":819,"NA":831},{"trials":812,"activeCount":97},[],{"trials":814,"activeCount":97},[],{"trials":816,"activeCount":97},[],{"trials":818,"activeCount":97},[],{"trials":820,"activeCount":97},[821],{"nctId":822,"briefTitle":823,"status":554,"phases":824,"primaryCompletion":825,"completion":826,"start":827,"enrollment":310,"conditions":828,"interventions":830},"NCT01477268","Cognitive Correlates of Antidepressant Treatment Response in Elders",[88],"2009-04","2009-10","2007-06",[829],"Depression",[809],{"trials":832,"activeCount":97},[],{"intervention":834,"totalTrials":93,"cells":835},"Desvenlafaxine",{"EARLY_PHASE1":836,"PHASE1":838,"PHASE2":840,"PHASE3":842,"PHASE4":844,"NA":856},{"trials":837,"activeCount":97},[],{"trials":839,"activeCount":97},[],{"trials":841,"activeCount":97},[],{"trials":843,"activeCount":97},[],{"trials":845,"activeCount":97},[846],{"nctId":847,"briefTitle":848,"status":554,"phases":849,"primaryCompletion":850,"completion":850,"start":851,"enrollment":852,"conditions":853,"interventions":855},"NCT02859103","Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Pre- and Post-Desvenlafaxine Treatment",[88],"2019-11-04","2017-06-01",56,[829,854],"Anhedonia",[834],{"trials":857,"activeCount":97},[],{"intervention":859,"totalTrials":93,"cells":860},"Nitrous Oxide 99 %",{"EARLY_PHASE1":861,"PHASE1":863,"PHASE2":865,"PHASE3":867,"PHASE4":869,"NA":880},{"trials":862,"activeCount":97},[],{"trials":864,"activeCount":97},[],{"trials":866,"activeCount":97},[],{"trials":868,"activeCount":97},[],{"trials":870,"activeCount":97},[871],{"nctId":872,"briefTitle":873,"status":554,"phases":874,"primaryCompletion":875,"completion":875,"start":876,"enrollment":167,"conditions":877,"interventions":878},"NCT04957368","Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial",[88],"2024-02-27","2021-11-03",[483,15],[859,879],"Oxygen + Midazolam",{"trials":881,"activeCount":97},[],{"intervention":879,"totalTrials":93,"cells":883},{"EARLY_PHASE1":884,"PHASE1":886,"PHASE2":888,"PHASE3":890,"PHASE4":892,"NA":898},{"trials":885,"activeCount":97},[],{"trials":887,"activeCount":97},[],{"trials":889,"activeCount":97},[],{"trials":891,"activeCount":97},[],{"trials":893,"activeCount":97},[894],{"nctId":872,"briefTitle":873,"status":554,"phases":895,"primaryCompletion":875,"completion":875,"start":876,"enrollment":167,"conditions":896,"interventions":897},[88],[483,15],[859,879],{"trials":899,"activeCount":97},[],{"intervention":901,"totalTrials":93,"cells":902},"PrEP",{"EARLY_PHASE1":903,"PHASE1":905,"PHASE2":907,"PHASE3":909,"PHASE4":911,"NA":922},{"trials":904,"activeCount":97},[],{"trials":906,"activeCount":97},[],{"trials":908,"activeCount":97},[],{"trials":910,"activeCount":97},[],{"trials":912,"activeCount":97},[913],{"nctId":914,"briefTitle":915,"status":542,"phases":916,"primaryCompletion":917,"completion":917,"start":918,"enrollment":290,"conditions":919,"interventions":921},"NCT05159531","Virtual PrEP: Rendering PrEP Delivery More Efficient",[88],"2023-06-08","2023-05-01",[920],"HIV Infections",[901],{"trials":923,"activeCount":97},[],{"intervention":925,"totalTrials":93,"cells":926},"Saxagliptin",{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":933,"PHASE4":935,"NA":947},{"trials":928,"activeCount":97},[],{"trials":930,"activeCount":97},[],{"trials":932,"activeCount":97},[],{"trials":934,"activeCount":97},[],{"trials":936,"activeCount":97},[937],{"nctId":938,"briefTitle":939,"status":554,"phases":940,"primaryCompletion":556,"completion":556,"start":941,"enrollment":11,"conditions":942,"interventions":945},"NCT02481479","Saxagliptin and Cardiac Structure and Function",[88],"2015-06",[943,944],"Diabetes Mellitus, Non-Insulin-Dependent","Heart Failure",[925,925,946],"saxagliptin",{"trials":948,"activeCount":97},[],{"intervention":950,"totalTrials":93,"cells":951},"Withdrawal of furosemide",{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":958,"PHASE4":960,"NA":973},{"trials":953,"activeCount":97},[],{"trials":955,"activeCount":97},[],{"trials":957,"activeCount":97},[],{"trials":959,"activeCount":97},[],{"trials":961,"activeCount":97},[962],{"nctId":963,"briefTitle":964,"status":566,"phases":965,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":971},"NCT01815892","The Use of Furosemide in Patients on Dialysis",[88],"2016-12","2015-05",51,[970],"End Stage Renal Disease",[950,972],"furosemide administration",{"trials":974,"activeCount":97},[],{"intervention":972,"totalTrials":93,"cells":976},{"EARLY_PHASE1":977,"PHASE1":979,"PHASE2":981,"PHASE3":983,"PHASE4":985,"NA":991},{"trials":978,"activeCount":97},[],{"trials":980,"activeCount":97},[],{"trials":982,"activeCount":97},[],{"trials":984,"activeCount":97},[],{"trials":986,"activeCount":97},[987],{"nctId":963,"briefTitle":964,"status":566,"phases":988,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":989,"interventions":990},[88],[970],[950,972],{"trials":992,"activeCount":97},[],{"intervention":994,"totalTrials":93,"cells":995},"Intravitreal ranibizumab",{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1002,"PHASE4":1004,"NA":1012},{"trials":997,"activeCount":97},[],{"trials":999,"activeCount":97},[],{"trials":1001,"activeCount":97},[],{"trials":1003,"activeCount":97},[],{"trials":1005,"activeCount":97},[1006],{"nctId":1007,"briefTitle":1008,"status":566,"phases":1009,"primaryCompletion":799,"completion":799,"start":800,"enrollment":801,"conditions":1010,"interventions":1011},"NCT03056092","Cytokine and Visual Outcome Variations in Eyes Receiving Ranibizumab",[88],[548,561,804,803],[994],{"trials":1013,"activeCount":97},[],{"intervention":1015,"totalTrials":93,"cells":1016},"Tenofovir\u002Femtricitabine",{"EARLY_PHASE1":1017,"PHASE1":1019,"PHASE2":1021,"PHASE3":1023,"PHASE4":1025,"NA":1037},{"trials":1018,"activeCount":97},[],{"trials":1020,"activeCount":97},[],{"trials":1022,"activeCount":97},[],{"trials":1024,"activeCount":97},[],{"trials":1026,"activeCount":97},[1027],{"nctId":1028,"briefTitle":1029,"status":554,"phases":1030,"primaryCompletion":1031,"completion":1031,"start":1032,"enrollment":1033,"conditions":1034,"interventions":1036},"NCT02149888","PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5",[88],"2016-06","2014-10",52,[21,1035],"Human Immunodeficiency Virus",[1015],{"trials":1038,"activeCount":97},[],{"intervention":1040,"totalTrials":93,"cells":1041},"Ketamine Hydrochloride",{"EARLY_PHASE1":1042,"PHASE1":1044,"PHASE2":1046,"PHASE3":1048,"PHASE4":1050,"NA":1061},{"trials":1043,"activeCount":97},[],{"trials":1045,"activeCount":97},[],{"trials":1047,"activeCount":97},[],{"trials":1049,"activeCount":97},[],{"trials":1051,"activeCount":97},[1052],{"nctId":1053,"briefTitle":1054,"status":554,"phases":1055,"primaryCompletion":1056,"completion":1056,"start":1057,"enrollment":310,"conditions":1058,"interventions":1060},"NCT05639322","Psychotherapy for Ketamine's Enhanced Durability in Chronic Neuropathic Pain: A Randomized Controlled Pilot Trial",[88],"2025-07-24","2023-10-12",[1059],"Neuropathic Pain",[1040],{"trials":1062,"activeCount":97},[],{"intervention":1064,"totalTrials":290,"cells":1065},"Tranexamic Acid 500 MG",{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1070,"PHASE3":1082,"PHASE4":1091,"NA":1093},{"trials":1067,"activeCount":97},[],{"trials":1069,"activeCount":97},[],{"trials":1071,"activeCount":97},[1072],{"nctId":1073,"briefTitle":1074,"status":566,"phases":1075,"primaryCompletion":1076,"completion":1076,"start":1077,"enrollment":1078,"conditions":1079,"interventions":1081},"NCT04898712","Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma -2",[86],"2023-12","2021-07",90,[1080],"Chronic Subdural Hematoma",[1064],{"trials":1083,"activeCount":97},[1084],{"nctId":1085,"briefTitle":1086,"status":566,"phases":1087,"primaryCompletion":568,"completion":568,"start":1088,"enrollment":409,"conditions":1089,"interventions":1090},"NCT03280212","Tranexamic Acid in the Treatment of Residual Chronic Subdural Hematoma",[87],"2017-03-06",[1080],[1064],{"trials":1092,"activeCount":97},[],{"trials":1094,"activeCount":97},[],{"intervention":1096,"totalTrials":93,"cells":1097},"Therapeutic Anticoagulation",{"EARLY_PHASE1":1098,"PHASE1":1100,"PHASE2":1102,"PHASE3":1104,"PHASE4":1116,"NA":1118},{"trials":1099,"activeCount":97},[],{"trials":1101,"activeCount":97},[],{"trials":1103,"activeCount":97},[],{"trials":1105,"activeCount":97},[1106],{"nctId":1107,"briefTitle":1108,"status":554,"phases":1109,"primaryCompletion":1110,"completion":1111,"start":1112,"enrollment":1113,"conditions":1114,"interventions":1115},"NCT04362085","Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care",[87],"2021-05-10","2021-10-14","2020-05-11",465,[192],[1096],{"trials":1117,"activeCount":97},[],{"trials":1119,"activeCount":97},[],{"intervention":1121,"totalTrials":93,"cells":1122},"Mirabegron 50 MG",{"EARLY_PHASE1":1123,"PHASE1":1125,"PHASE2":1127,"PHASE3":1129,"PHASE4":1142,"NA":1144},{"trials":1124,"activeCount":97},[],{"trials":1126,"activeCount":97},[],{"trials":1128,"activeCount":97},[],{"trials":1130,"activeCount":97},[1131],{"nctId":1132,"briefTitle":1133,"status":566,"phases":1134,"primaryCompletion":1135,"completion":1136,"start":1137,"enrollment":1138,"conditions":1139,"interventions":1141},"NCT04286152","Mirabegron And Ureteral Stent-related Pain (MAP) Trial",[87],"2021-02-28","2021-06-30","2020-02-03",142,[1140],"Nephrolithiasis",[1121],{"trials":1143,"activeCount":97},[],{"trials":1145,"activeCount":97},[],{"intervention":1147,"totalTrials":93,"cells":1148},"Lopinavir\u002Fritonavir",{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1155,"PHASE4":1169,"NA":1171},{"trials":1150,"activeCount":97},[],{"trials":1152,"activeCount":97},[],{"trials":1154,"activeCount":97},[],{"trials":1156,"activeCount":97},[1157],{"nctId":1158,"briefTitle":1159,"status":566,"phases":1160,"primaryCompletion":1161,"completion":1162,"start":1163,"enrollment":1164,"conditions":1165,"interventions":1168},"NCT04321174","COVID-19 Ring-based Prevention Trial With Lopinavir\u002FRitonavir",[87],"2021-08-27","2022-03-31","2020-04-17",123,[1166,1167],"Coronavirus Infections","Post-exposure Prophylaxis",[1147],{"trials":1170,"activeCount":97},[],{"trials":1172,"activeCount":97},[],{"intervention":1174,"totalTrials":93,"cells":1175},"0.9% NaCl",{"EARLY_PHASE1":1176,"PHASE1":1178,"PHASE2":1180,"PHASE3":1182,"PHASE4":1196,"NA":1198},{"trials":1177,"activeCount":97},[],{"trials":1179,"activeCount":97},[],{"trials":1181,"activeCount":97},[],{"trials":1183,"activeCount":97},[1184],{"nctId":1185,"briefTitle":1186,"status":554,"phases":1187,"primaryCompletion":1188,"completion":1189,"start":1190,"enrollment":1191,"conditions":1192,"interventions":1194},"NCT02636218","Ketamine Infusion in Neurologic Deficit",[86,87],"2021-03-31","2023-11-15","2016-01-26",9,[1193],"Subarachnoid Hemorrhage",[1195,1174],"Ketamine",{"trials":1197,"activeCount":97},[],{"trials":1199,"activeCount":97},[],{"intervention":1201,"totalTrials":93,"cells":1202},"Antimicrobial",{"EARLY_PHASE1":1203,"PHASE1":1205,"PHASE2":1207,"PHASE3":1209,"PHASE4":1220,"NA":1222},{"trials":1204,"activeCount":97},[],{"trials":1206,"activeCount":97},[],{"trials":1208,"activeCount":97},[],{"trials":1210,"activeCount":97},[1211],{"nctId":1212,"briefTitle":1213,"status":701,"phases":1214,"primaryCompletion":1215,"completion":1215,"start":1216,"enrollment":97,"conditions":1217,"interventions":1219},"NCT00795470","Factorial Trial of Antimicrobial Therapy and\u002For Catheter Change for Catheter Urinary Tract Infections.",[87],"2014-01","2012-01",[1218],"Urinary Tract Infections",[1201],{"trials":1221,"activeCount":97},[],{"trials":1223,"activeCount":97},[],{"intervention":1225,"totalTrials":93,"cells":1226},"Cannabinol",{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1233,"PHASE4":1246,"NA":1248},{"trials":1228,"activeCount":97},[],{"trials":1230,"activeCount":97},[],{"trials":1232,"activeCount":97},[],{"trials":1234,"activeCount":97},[1235],{"nctId":1236,"briefTitle":1237,"status":566,"phases":1238,"primaryCompletion":1239,"completion":1240,"start":1241,"enrollment":1242,"conditions":1243,"interventions":1245},"NCT03675971","COPE: Cannabinoids to Obviate Pain Experiment After Knee Replacement",[86,87],"2021-05-15","2022-05","2020-05-01",220,[1244],"Arthroplasty, Replacement, Knee",[1225],{"trials":1247,"activeCount":97},[],{"trials":1249,"activeCount":97},[],{"intervention":1251,"totalTrials":93,"cells":1252},"Modafinil",{"EARLY_PHASE1":1253,"PHASE1":1255,"PHASE2":1257,"PHASE3":1259,"PHASE4":1270,"NA":1272},{"trials":1254,"activeCount":97},[],{"trials":1256,"activeCount":97},[],{"trials":1258,"activeCount":97},[],{"trials":1260,"activeCount":97},[1261],{"nctId":1262,"briefTitle":1263,"status":542,"phases":1264,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":1191,"conditions":1267,"interventions":1269},"NCT03620253","Modafinil's Effects on Cognition in Remitted MDD",[87],"2019-08-06","2018-10-15",[15,1268],"Cognitive Impairment",[1251],{"trials":1271,"activeCount":97},[],{"trials":1273,"activeCount":97},[],{"intervention":1275,"totalTrials":93,"cells":1276},"N-acetylcysteine",{"EARLY_PHASE1":1277,"PHASE1":1279,"PHASE2":1281,"PHASE3":1283,"PHASE4":1297,"NA":1299},{"trials":1278,"activeCount":97},[],{"trials":1280,"activeCount":97},[],{"trials":1282,"activeCount":97},[],{"trials":1284,"activeCount":97},[1285],{"nctId":1286,"briefTitle":1287,"status":554,"phases":1288,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1295},"NCT00830193","N-Acetylcysteine in Critically Ill Patients Undergoing Contrast Enhanced Computed Tomography",[86,87],"2005-05","2002-08",45,[1293,1294],"Contrast Induced Nephropathy","Critically Ill",[1275,1296],"D5W Placebo",{"trials":1298,"activeCount":97},[],{"trials":1300,"activeCount":97},[],{"intervention":1296,"totalTrials":93,"cells":1302},{"EARLY_PHASE1":1303,"PHASE1":1305,"PHASE2":1307,"PHASE3":1309,"PHASE4":1315,"NA":1317},{"trials":1304,"activeCount":97},[],{"trials":1306,"activeCount":97},[],{"trials":1308,"activeCount":97},[],{"trials":1310,"activeCount":97},[1311],{"nctId":1286,"briefTitle":1287,"status":554,"phases":1312,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":1291,"conditions":1313,"interventions":1314},[86,87],[1293,1294],[1275,1296],{"trials":1316,"activeCount":97},[],{"trials":1318,"activeCount":97},[],{"intervention":1320,"totalTrials":93,"cells":1321},"Oseltamivir",{"EARLY_PHASE1":1322,"PHASE1":1324,"PHASE2":1326,"PHASE3":1328,"PHASE4":1338,"NA":1340},{"trials":1323,"activeCount":97},[],{"trials":1325,"activeCount":97},[],{"trials":1327,"activeCount":97},[],{"trials":1329,"activeCount":97},[1330],{"nctId":1331,"briefTitle":1332,"status":566,"phases":1333,"primaryCompletion":1334,"completion":1334,"start":664,"enrollment":310,"conditions":1335,"interventions":1337},"NCT03520049","Proof-of-Concept: A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia",[87],"2021-09",[1336],"Immune Thrombocytopenia",[1320],{"trials":1339,"activeCount":97},[],{"trials":1341,"activeCount":97},[],{"intervention":1343,"totalTrials":93,"cells":1344},"Pegvisomant",{"EARLY_PHASE1":1345,"PHASE1":1347,"PHASE2":1349,"PHASE3":1351,"PHASE4":1362,"NA":1364},{"trials":1346,"activeCount":97},[],{"trials":1348,"activeCount":97},[],{"trials":1350,"activeCount":97},[],{"trials":1352,"activeCount":97},[1353],{"nctId":1354,"briefTitle":1355,"status":554,"phases":1356,"primaryCompletion":1357,"completion":1357,"start":1358,"enrollment":607,"conditions":1359,"interventions":1361},"NCT02952885","Strict IGF-1 Control in Acromegaly",[87],"2020-05-07","2017-07-27",[1360],"Acromegaly",[1343],{"trials":1363,"activeCount":97},[],{"trials":1365,"activeCount":97},[],{"intervention":670,"totalTrials":93,"cells":1367},{"EARLY_PHASE1":1368,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1380,"NA":1382},{"trials":1369,"activeCount":97},[],{"trials":1371,"activeCount":97},[],{"trials":1373,"activeCount":97},[],{"trials":1375,"activeCount":97},[1376],{"nctId":660,"briefTitle":661,"status":554,"phases":1377,"primaryCompletion":663,"completion":664,"start":665,"enrollment":666,"conditions":1378,"interventions":1379},[87],[668],[649,670],{"trials":1381,"activeCount":97},[],{"trials":1383,"activeCount":97},[],{"intervention":597,"totalTrials":93,"cells":1385},{"EARLY_PHASE1":1386,"PHASE1":1388,"PHASE2":1390,"PHASE3":1392,"PHASE4":1398,"NA":1400},{"trials":1387,"activeCount":97},[],{"trials":1389,"activeCount":97},[],{"trials":1391,"activeCount":97},[],{"trials":1393,"activeCount":97},[1394],{"nctId":587,"briefTitle":588,"status":554,"phases":1395,"primaryCompletion":590,"completion":591,"start":592,"enrollment":593,"conditions":1396,"interventions":1397},[86,87],[595],[597,576],{"trials":1399,"activeCount":97},[],{"trials":1401,"activeCount":97},[],{"intervention":1403,"totalTrials":93,"cells":1404},"Doxycycline Hyclate",{"EARLY_PHASE1":1405,"PHASE1":1407,"PHASE2":1409,"PHASE3":1422,"PHASE4":1424,"NA":1426},{"trials":1406,"activeCount":97},[],{"trials":1408,"activeCount":97},[],{"trials":1410,"activeCount":97},[1411],{"nctId":1412,"briefTitle":1413,"status":554,"phases":1414,"primaryCompletion":1415,"completion":1416,"start":1417,"enrollment":1418,"conditions":1419,"interventions":1421},"NCT03397004","Doxycycline for Hereditary Hemorrhagic Telangiectasia",[86],"2021-02-18","2021-03-01","2018-09-12",13,[1420],"Hereditary Hemorrhagic Telangiectasia (HHT)",[1403],{"trials":1423,"activeCount":97},[],{"trials":1425,"activeCount":97},[],{"trials":1427,"activeCount":97},[],{"intervention":1429,"totalTrials":93,"cells":1430},"Tacrolimus",{"EARLY_PHASE1":1431,"PHASE1":1433,"PHASE2":1435,"PHASE3":1447,"PHASE4":1449,"NA":1451},{"trials":1432,"activeCount":97},[],{"trials":1434,"activeCount":97},[],{"trials":1436,"activeCount":97},[1437],{"nctId":1438,"briefTitle":1439,"status":554,"phases":1440,"primaryCompletion":1441,"completion":258,"start":1442,"enrollment":607,"conditions":1443,"interventions":1446},"NCT04646356","Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)",[86],"2024-01-15","2020-10-20",[1444,1445],"Hereditary Hemorrhagic Telangiectasia","Epistaxis Nosebleed",[1429],{"trials":1448,"activeCount":97},[],{"trials":1450,"activeCount":97},[],{"trials":1452,"activeCount":97},[],{"intervention":1454,"totalTrials":93,"cells":1455},"Furosemide",{"EARLY_PHASE1":1456,"PHASE1":1458,"PHASE2":1460,"PHASE3":1476,"PHASE4":1478,"NA":1480},{"trials":1457,"activeCount":97},[],{"trials":1459,"activeCount":97},[],{"trials":1461,"activeCount":97},[1462],{"nctId":1463,"briefTitle":1464,"status":566,"phases":1465,"primaryCompletion":1466,"completion":1467,"start":1468,"enrollment":776,"conditions":1469,"interventions":1474},"NCT06326112","Role of Active Deresuscitation After Resuscitation:",[86],"2025-03-31","2025-06-30","2024-05-01",[1470,1471,1472,1473,504],"Fluid Overload","Critical Illness","Sepsis","ARDS",[1454,1475],"Metolazone",{"trials":1477,"activeCount":97},[],{"trials":1479,"activeCount":97},[],{"trials":1481,"activeCount":97},[],{"intervention":1475,"totalTrials":93,"cells":1483},{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1488,"PHASE3":1494,"PHASE4":1496,"NA":1498},{"trials":1485,"activeCount":97},[],{"trials":1487,"activeCount":97},[],{"trials":1489,"activeCount":97},[1490],{"nctId":1463,"briefTitle":1464,"status":566,"phases":1491,"primaryCompletion":1466,"completion":1467,"start":1468,"enrollment":776,"conditions":1492,"interventions":1493},[86],[1470,1471,1472,1473,504],[1454,1475],{"trials":1495,"activeCount":97},[],{"trials":1497,"activeCount":97},[],{"trials":1499,"activeCount":97},[],{"intervention":1501,"totalTrials":93,"cells":1502},"Sildenafil",{"EARLY_PHASE1":1503,"PHASE1":1505,"PHASE2":1507,"PHASE3":1518,"PHASE4":1520,"NA":1522},{"trials":1504,"activeCount":97},[],{"trials":1506,"activeCount":97},[],{"trials":1508,"activeCount":97},[1509],{"nctId":1510,"briefTitle":1511,"status":554,"phases":1512,"primaryCompletion":825,"completion":1513,"start":1514,"enrollment":167,"conditions":1515,"interventions":1517},"NCT00334490","Does Oral Sildenafil (Viagra) Decrease Mean Pulmonary Artery Pressure After Cardiac Surgery?",[86],"2009-05","2005-03",[1516],"Pulmonary Hypertension",[1501,1501],{"trials":1519,"activeCount":97},[],{"trials":1521,"activeCount":97},[],{"trials":1523,"activeCount":97},[],{"intervention":1525,"totalTrials":93,"cells":1526},"Nabilone",{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1544,"PHASE4":1546,"NA":1548},{"trials":1528,"activeCount":97},[],{"trials":1530,"activeCount":97},[],{"trials":1532,"activeCount":97},[1533],{"nctId":1534,"briefTitle":1535,"status":554,"phases":1536,"primaryCompletion":1537,"completion":1538,"start":1539,"enrollment":1540,"conditions":1541,"interventions":1543},"NCT02115529","Study of Prevention of Postoperative Nausea and Vomiting Using Cesamet",[86],"2015-01","2015-11","2014-04",331,[1542],"Postoperative Nausea and Vomiting",[1525],{"trials":1545,"activeCount":97},[],{"trials":1547,"activeCount":97},[],{"trials":1549,"activeCount":97},[],{"intervention":1551,"totalTrials":93,"cells":1552},"Azithromycin",{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1568,"PHASE4":1570,"NA":1572},{"trials":1554,"activeCount":97},[],{"trials":1556,"activeCount":97},[],{"trials":1558,"activeCount":97},[1559],{"nctId":1560,"briefTitle":1561,"status":566,"phases":1562,"primaryCompletion":1563,"completion":826,"start":1564,"enrollment":1291,"conditions":1565,"interventions":1567},"NCT00298922","Azithromycin in Patients With CF, Infected With Burkholderia Cepacia Complex",[86],"2009-02","2006-02",[1566],"Cystic Fibrosis",[1551],{"trials":1569,"activeCount":97},[],{"trials":1571,"activeCount":97},[],{"trials":1573,"activeCount":97},[],{"intervention":1575,"totalTrials":93,"cells":1576},"Iron sucrose",{"EARLY_PHASE1":1577,"PHASE1":1579,"PHASE2":1581,"PHASE3":1597,"PHASE4":1599,"NA":1601},{"trials":1578,"activeCount":97},[],{"trials":1580,"activeCount":97},[],{"trials":1582,"activeCount":97},[1583],{"nctId":1584,"briefTitle":1585,"status":542,"phases":1586,"primaryCompletion":1587,"completion":1587,"start":1588,"enrollment":1589,"conditions":1590,"interventions":1595},"NCT03528564","Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia",[86],"2021-05-31","2019-07-01",4,[1591,1592,1593,1594],"Anemia, Iron Deficiency","Anemia of Chronic Disease","Hip Arthropathy","Knee Arthropathy",[1575,1596],"Epoetin Alfa",{"trials":1598,"activeCount":97},[],{"trials":1600,"activeCount":97},[],{"trials":1602,"activeCount":97},[],{"intervention":1596,"totalTrials":93,"cells":1604},{"EARLY_PHASE1":1605,"PHASE1":1607,"PHASE2":1609,"PHASE3":1615,"PHASE4":1617,"NA":1619},{"trials":1606,"activeCount":97},[],{"trials":1608,"activeCount":97},[],{"trials":1610,"activeCount":97},[1611],{"nctId":1584,"briefTitle":1585,"status":542,"phases":1612,"primaryCompletion":1587,"completion":1587,"start":1588,"enrollment":1589,"conditions":1613,"interventions":1614},[86],[1591,1592,1593,1594],[1575,1596],{"trials":1616,"activeCount":97},[],{"trials":1618,"activeCount":97},[],{"trials":1620,"activeCount":97},[],{"intervention":1622,"totalTrials":93,"cells":1623},"Danazol",{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1628,"PHASE3":1638,"PHASE4":1640,"NA":1642},{"trials":1625,"activeCount":97},[],{"trials":1627,"activeCount":97},[],{"trials":1629,"activeCount":97},[1630],{"nctId":1631,"briefTitle":1632,"status":554,"phases":1633,"primaryCompletion":775,"completion":775,"start":1634,"enrollment":1635,"conditions":1636,"interventions":1637},"NCT02002403","Efficacy and Safety Study to Evaluate Two Doses of Oral DMI-5207 in Adult Subjects With Diabetic Macular Edema",[86],"2011-01",34,[561],[1622],{"trials":1639,"activeCount":97},[],{"trials":1641,"activeCount":97},[],{"trials":1643,"activeCount":97},[],{"intervention":1645,"totalTrials":93,"cells":1646},"Triamcinolone Acetonide",{"EARLY_PHASE1":1647,"PHASE1":1649,"PHASE2":1651,"PHASE3":1660,"PHASE4":1662,"NA":1664},{"trials":1648,"activeCount":97},[],{"trials":1650,"activeCount":97},[],{"trials":1652,"activeCount":97},[1653],{"nctId":1654,"briefTitle":1655,"status":554,"phases":1656,"primaryCompletion":966,"completion":966,"start":1657,"enrollment":527,"conditions":1658,"interventions":1659},"NCT02221453","Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide",[86],"2015-09",[561],[1645],{"trials":1661,"activeCount":97},[],{"trials":1663,"activeCount":97},[],{"trials":1665,"activeCount":97},[],{"intervention":1667,"totalTrials":93,"cells":1668},"Calcium carbonate",{"EARLY_PHASE1":1669,"PHASE1":1671,"PHASE2":1673,"PHASE3":1684,"PHASE4":1686,"NA":1688},{"trials":1670,"activeCount":97},[],{"trials":1672,"activeCount":97},[],{"trials":1674,"activeCount":97},[1675],{"nctId":1676,"briefTitle":1677,"status":554,"phases":1678,"primaryCompletion":1679,"completion":1679,"start":1215,"enrollment":1680,"conditions":1681,"interventions":1683},"NCT01994733","Two phosphAte taRGets in End-stage Renal Disease Trial (TARGET)",[86],"2015-04",104,[1682],"End-stage Renal Disease",[1667,1667],{"trials":1685,"activeCount":97},[],{"trials":1687,"activeCount":97},[],{"trials":1689,"activeCount":97},[],{"intervention":1691,"totalTrials":93,"cells":1692},"nPEP",{"EARLY_PHASE1":1693,"PHASE1":1695,"PHASE2":1697,"PHASE3":1708,"PHASE4":1710,"NA":1712},{"trials":1694,"activeCount":97},[],{"trials":1696,"activeCount":97},[],{"trials":1698,"activeCount":97},[1699],{"nctId":1700,"briefTitle":1701,"status":566,"phases":1702,"primaryCompletion":1703,"completion":1704,"start":1705,"enrollment":6,"conditions":1706,"interventions":1707},"NCT03259698","Optimizing the Delivery of HIV nPEP",[86],"2022-12","2023-08","2021-11-04",[920],[1691],{"trials":1709,"activeCount":97},[],{"trials":1711,"activeCount":97},[],{"trials":1713,"activeCount":97},[],{"intervention":1715,"totalTrials":93,"cells":1716},"Norfloxacin",{"EARLY_PHASE1":1717,"PHASE1":1719,"PHASE2":1721,"PHASE3":1733,"PHASE4":1735,"NA":1737},{"trials":1718,"activeCount":97},[],{"trials":1720,"activeCount":97},[],{"trials":1722,"activeCount":97},[1723],{"nctId":1724,"briefTitle":1725,"status":554,"phases":1726,"primaryCompletion":1727,"completion":1728,"start":1729,"enrollment":1191,"conditions":1730,"interventions":1732},"NCT00362752","A Pilot Study of Norfloxacin for Hepatopulmonary Syndrome",[86],"2009-01","2009-12","2006-10",[1731],"Hepatopulmonary Syndrome",[1715],{"trials":1734,"activeCount":97},[],{"trials":1736,"activeCount":97},[],{"trials":1738,"activeCount":97},[],{"intervention":1740,"totalTrials":93,"cells":1741},"Warfarin",{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1760,"PHASE4":1762,"NA":1764},{"trials":1743,"activeCount":97},[],{"trials":1745,"activeCount":97},[],{"trials":1747,"activeCount":97},[1748],{"nctId":1749,"briefTitle":1750,"status":554,"phases":1751,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":1754,"conditions":1755,"interventions":1758},"NCT03987711","Strategies for the Management of Atrial Fibrillation in patiEnts Receiving Dialysis",[86],"2022-12-31","2019-12-10",151,[1756,1757],"Atrial Fibrillation","End Stage Renal Failure on Dialysis",[1740,1759],"Apixaban",{"trials":1761,"activeCount":97},[],{"trials":1763,"activeCount":97},[],{"trials":1765,"activeCount":97},[],{"intervention":1759,"totalTrials":93,"cells":1767},{"EARLY_PHASE1":1768,"PHASE1":1770,"PHASE2":1772,"PHASE3":1778,"PHASE4":1780,"NA":1782},{"trials":1769,"activeCount":97},[],{"trials":1771,"activeCount":97},[],{"trials":1773,"activeCount":97},[1774],{"nctId":1749,"briefTitle":1750,"status":554,"phases":1775,"primaryCompletion":1752,"completion":1752,"start":1753,"enrollment":1754,"conditions":1776,"interventions":1777},[86],[1756,1757],[1740,1759],{"trials":1779,"activeCount":97},[],{"trials":1781,"activeCount":97},[],{"trials":1783,"activeCount":97},[],{"intervention":1785,"totalTrials":93,"cells":1786},"Phage Therapy",{"EARLY_PHASE1":1787,"PHASE1":1789,"PHASE2":1791,"PHASE3":1802,"PHASE4":1804,"NA":1806},{"trials":1788,"activeCount":97},[],{"trials":1790,"activeCount":97},[],{"trials":1792,"activeCount":97},[1793],{"nctId":1794,"briefTitle":1795,"status":566,"phases":1796,"primaryCompletion":1797,"completion":1798,"start":918,"enrollment":93,"conditions":1799,"interventions":1801},"NCT05537519","Phage Therapy for the Treatment of Urinary Tract Infection",[85,86],"2023-07-28","2024-06-30",[1800],"Recurrent Urinary Tract Infection",[1785],{"trials":1803,"activeCount":97},[],{"trials":1805,"activeCount":97},[],{"trials":1807,"activeCount":97},[],{"intervention":1809,"totalTrials":93,"cells":1810},"Sirolimus",{"EARLY_PHASE1":1811,"PHASE1":1813,"PHASE2":1815,"PHASE3":1827,"PHASE4":1829,"NA":1831},{"trials":1812,"activeCount":97},[],{"trials":1814,"activeCount":97},[],{"trials":1816,"activeCount":97},[1817],{"nctId":1818,"briefTitle":1819,"status":554,"phases":1820,"primaryCompletion":1821,"completion":1821,"start":1822,"enrollment":607,"conditions":1823,"interventions":1826},"NCT05269849","Sirolimus for Nosebleeds in HHT",[86],"2024-12-02","2022-03-16",[1444,1824,1825],"Nosebleeds","Epistaxis",[1809],{"trials":1828,"activeCount":97},[],{"trials":1830,"activeCount":97},[],{"trials":1832,"activeCount":97},[],{"intervention":1834,"totalTrials":93,"cells":1835},"Topical timolol maleate",{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1840,"PHASE3":1851,"PHASE4":1853,"NA":1855},{"trials":1837,"activeCount":97},[],{"trials":1839,"activeCount":97},[],{"trials":1841,"activeCount":97},[1842],{"nctId":1843,"briefTitle":1844,"status":554,"phases":1845,"primaryCompletion":1846,"completion":1846,"start":1847,"enrollment":1848,"conditions":1849,"interventions":1850},"NCT01752049","Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept",[85,86],"2019-08-30","2013-05",5,[1444],[1834],{"trials":1852,"activeCount":97},[],{"trials":1854,"activeCount":97},[],{"trials":1856,"activeCount":97},[],{"intervention":1858,"totalTrials":93,"cells":1859},"alendronate\u002Fvitamin D",{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1864,"PHASE3":1874,"PHASE4":1876,"NA":1878},{"trials":1861,"activeCount":97},[],{"trials":1863,"activeCount":97},[],{"trials":1865,"activeCount":97},[1866],{"nctId":1867,"briefTitle":1868,"status":554,"phases":1869,"primaryCompletion":1870,"completion":1870,"start":1871,"enrollment":310,"conditions":1872,"interventions":1873},"NCT01968850","Bone Antiresorptive Therapy With Antiretroviral Initiation (BATARI) Pilot Trial",[86],"2018-03-19","2014-04-23",[21],[1858],{"trials":1875,"activeCount":97},[],{"trials":1877,"activeCount":97},[],{"trials":1879,"activeCount":97},[],{"intervention":1881,"totalTrials":93,"cells":1882},"Etanercept",{"EARLY_PHASE1":1883,"PHASE1":1885,"PHASE2":1896,"PHASE3":1898,"PHASE4":1900,"NA":1902},{"trials":1884,"activeCount":97},[],{"trials":1886,"activeCount":97},[1887],{"nctId":1888,"briefTitle":1889,"status":701,"phases":1890,"primaryCompletion":1891,"completion":1891,"start":1892,"enrollment":97,"conditions":1893,"interventions":1895},"NCT01865630","Safety and Efficacy Study of Etanercept for Aneurysmal Subarachnoid Hemorrhage",[85],"2022-01","2021-01",[1894],"Subarachnoid Hemorrhage, Aneurysmal",[1881],{"trials":1897,"activeCount":97},[],{"trials":1899,"activeCount":97},[],{"trials":1901,"activeCount":97},[],{"trials":1903,"activeCount":97},[],{"intervention":1905,"totalTrials":93,"cells":1906},"TOBI",{"EARLY_PHASE1":1907,"PHASE1":1909,"PHASE2":1920,"PHASE3":1922,"PHASE4":1924,"NA":1926},{"trials":1908,"activeCount":97},[],{"trials":1910,"activeCount":97},[1911],{"nctId":1912,"briefTitle":1913,"status":554,"phases":1914,"primaryCompletion":1915,"completion":1915,"start":1916,"enrollment":607,"conditions":1917,"interventions":1919},"NCT02212587","Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex",[85],"2016-05","2014-09",[1566,1918],"Burkholderia Cepacia Infection",[1905],{"trials":1921,"activeCount":97},[],{"trials":1923,"activeCount":97},[],{"trials":1925,"activeCount":97},[],{"trials":1927,"activeCount":97},[],{"intervention":1929,"totalTrials":93,"cells":1930},"Cannabis",{"EARLY_PHASE1":1931,"PHASE1":1933,"PHASE2":1945,"PHASE3":1947,"PHASE4":1949,"NA":1951},{"trials":1932,"activeCount":97},[],{"trials":1934,"activeCount":97},[1935],{"nctId":1936,"briefTitle":1937,"status":566,"phases":1938,"primaryCompletion":1939,"completion":1939,"start":1940,"enrollment":16,"conditions":1941,"interventions":1944},"NCT03581058","Neural Correlates of Driving and Cannabis",[85],"2020-12-31","2018-08-08",[1942,1943],"Cannabis Use","Driving Impaired",[1929],{"trials":1946,"activeCount":97},[],{"trials":1948,"activeCount":97},[],{"trials":1950,"activeCount":97},[],{"trials":1952,"activeCount":97},[],{"intervention":1195,"totalTrials":290,"cells":1954},{"EARLY_PHASE1":1955,"PHASE1":1957,"PHASE2":1959,"PHASE3":1961,"PHASE4":1967,"NA":1969},{"trials":1956,"activeCount":97},[],{"trials":1958,"activeCount":97},[],{"trials":1960,"activeCount":97},[],{"trials":1962,"activeCount":97},[1963],{"nctId":1185,"briefTitle":1186,"status":554,"phases":1964,"primaryCompletion":1188,"completion":1189,"start":1190,"enrollment":1191,"conditions":1965,"interventions":1966},[86,87],[1193],[1195,1174],{"trials":1968,"activeCount":97},[],{"trials":1970,"activeCount":97},[1971],{"nctId":1972,"briefTitle":1973,"status":566,"phases":1974,"primaryCompletion":1975,"completion":1976,"start":1977,"enrollment":310,"conditions":1978,"interventions":1980},"NCT05464264","Auditory MMN EEG in TRD in Response to Ketamine",[],"2024-10","2024-12","2022-10-03",[1979],"Treatment-resistant Depression (TRD)",[1195],{"intervention":1982,"totalTrials":93,"cells":1983},"Alfuzosin",{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1988,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1985,"activeCount":97},[],{"trials":1987,"activeCount":97},[],{"trials":1989,"activeCount":97},[],{"trials":1991,"activeCount":97},[],{"trials":1993,"activeCount":97},[],{"trials":1995,"activeCount":97},[1996],{"nctId":1997,"briefTitle":1998,"status":701,"phases":1999,"primaryCompletion":2000,"completion":826,"start":2001,"enrollment":97,"conditions":2002,"interventions":2004},"NCT00583258","A Randomized Study of Whether Alfuzosin(Xatral) Helps in the Passage of Kidney Stones",[89],"2009-09","2007-10",[2003],"Kidney Stones",[1982],{"intervention":2006,"totalTrials":93,"cells":2007},"Nitrous oxide gas for inhalation",{"EARLY_PHASE1":2008,"PHASE1":2010,"PHASE2":2012,"PHASE3":2014,"PHASE4":2016,"NA":2018},{"trials":2009,"activeCount":97},[],{"trials":2011,"activeCount":97},[],{"trials":2013,"activeCount":97},[],{"trials":2015,"activeCount":97},[],{"trials":2017,"activeCount":97},[],{"trials":2019,"activeCount":97},[2020],{"nctId":2021,"briefTitle":2022,"status":554,"phases":2023,"primaryCompletion":2024,"completion":2025,"start":2026,"enrollment":2027,"conditions":2028,"interventions":2029},"NCT05528718","SMILE Trial - Imaging Sub-Study",[],"2024-03-30","2024-06-14","2023-03-07",11,[15],[2006,2030],"Midazolam",{"intervention":2030,"totalTrials":93,"cells":2032},{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2039,"PHASE4":2041,"NA":2043},{"trials":2034,"activeCount":97},[],{"trials":2036,"activeCount":97},[],{"trials":2038,"activeCount":97},[],{"trials":2040,"activeCount":97},[],{"trials":2042,"activeCount":97},[],{"trials":2044,"activeCount":97},[2045],{"nctId":2021,"briefTitle":2022,"status":554,"phases":2046,"primaryCompletion":2024,"completion":2025,"start":2026,"enrollment":2027,"conditions":2047,"interventions":2048},[],[15],[2006,2030],{"intervention":2050,"totalTrials":93,"cells":2051},"Urine sample collection",{"EARLY_PHASE1":2052,"PHASE1":2054,"PHASE2":2056,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2053,"activeCount":97},[],{"trials":2055,"activeCount":97},[],{"trials":2057,"activeCount":97},[],{"trials":2059,"activeCount":97},[],{"trials":2061,"activeCount":97},[],{"trials":2063,"activeCount":97},[2064],{"nctId":2065,"briefTitle":2066,"status":554,"phases":2067,"primaryCompletion":641,"completion":641,"start":1916,"enrollment":2068,"conditions":2069,"interventions":2071},"NCT03064412","Effect of Pregnancy on Androgenic Steroids in Different Genetic Panels",[89],70,[2070],"Sex Steroids",[2050,2072],"Saliva collection",{"intervention":2072,"totalTrials":93,"cells":2074},{"EARLY_PHASE1":2075,"PHASE1":2077,"PHASE2":2079,"PHASE3":2081,"PHASE4":2083,"NA":2085},{"trials":2076,"activeCount":97},[],{"trials":2078,"activeCount":97},[],{"trials":2080,"activeCount":97},[],{"trials":2082,"activeCount":97},[],{"trials":2084,"activeCount":97},[],{"trials":2086,"activeCount":97},[2087],{"nctId":2065,"briefTitle":2066,"status":554,"phases":2088,"primaryCompletion":641,"completion":641,"start":1916,"enrollment":2068,"conditions":2089,"interventions":2090},[89],[2070],[2050,2072],{"intervention":2092,"totalTrials":93,"cells":2093},"Floseal",{"EARLY_PHASE1":2094,"PHASE1":2096,"PHASE2":2098,"PHASE3":2100,"PHASE4":2102,"NA":2104},{"trials":2095,"activeCount":97},[],{"trials":2097,"activeCount":97},[],{"trials":2099,"activeCount":97},[],{"trials":2101,"activeCount":97},[],{"trials":2103,"activeCount":97},[],{"trials":2105,"activeCount":97},[2106],{"nctId":2107,"briefTitle":2108,"status":554,"phases":2109,"primaryCompletion":2110,"completion":2111,"start":2112,"enrollment":19,"conditions":2113,"interventions":2114},"NCT02638012","Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT)",[89],"2019-10","2019-12","2015-12",[1420,1825],[2092],{"intervention":2116,"totalTrials":93,"cells":2117},"Non-Selective Beta Blockers",{"EARLY_PHASE1":2118,"PHASE1":2120,"PHASE2":2122,"PHASE3":2124,"PHASE4":2126,"NA":2128},{"trials":2119,"activeCount":97},[],{"trials":2121,"activeCount":97},[],{"trials":2123,"activeCount":97},[],{"trials":2125,"activeCount":97},[],{"trials":2127,"activeCount":97},[],{"trials":2129,"activeCount":97},[2130],{"nctId":2131,"briefTitle":2132,"status":701,"phases":2133,"primaryCompletion":2134,"completion":2135,"start":2136,"enrollment":97,"conditions":2137,"interventions":2140},"NCT05859009","Primary Prevention of Gastric Varices Bleed",[89],"2025-07-01","2026-07-01","2023-07-01",[2138,2139],"Gastric Varices Bleeding","Endoscopic Ultrasound",[2116],{"intervention":2142,"totalTrials":93,"cells":2143},"Vaginal and blood sample collection",{"EARLY_PHASE1":2144,"PHASE1":2146,"PHASE2":2148,"PHASE3":2150,"PHASE4":2152,"NA":2154},{"trials":2145,"activeCount":97},[],{"trials":2147,"activeCount":97},[],{"trials":2149,"activeCount":97},[],{"trials":2151,"activeCount":97},[],{"trials":2153,"activeCount":97},[],{"trials":2155,"activeCount":97},[2156],{"nctId":2157,"briefTitle":2158,"status":554,"phases":2159,"primaryCompletion":641,"completion":641,"start":1537,"enrollment":2160,"conditions":2161,"interventions":2162},"NCT03064425","Understanding HIV Susceptibility in the Female Genital Tract",[],98,[920],[2142],{"intervention":2164,"totalTrials":93,"cells":2165},"Sacubitril\u002FValsartan",{"EARLY_PHASE1":2166,"PHASE1":2168,"PHASE2":2170,"PHASE3":2172,"PHASE4":2174,"NA":2176},{"trials":2167,"activeCount":97},[],{"trials":2169,"activeCount":97},[],{"trials":2171,"activeCount":97},[],{"trials":2173,"activeCount":97},[],{"trials":2175,"activeCount":97},[],{"trials":2177,"activeCount":97},[2178],{"nctId":2179,"briefTitle":2180,"status":566,"phases":2181,"primaryCompletion":2182,"completion":2183,"start":1031,"enrollment":2184,"conditions":2185,"interventions":2186},"NCT04107220","Comparison of BNP and NT-proBNP in the Management of Patients With Chronic and Acute Heart Failure",[89],"2017-05","2020-06",300,[944],[2164],{"intervention":2188,"totalTrials":93,"cells":2189},"Phenobarbital Sodium",{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2196,"PHASE4":2198,"NA":2200},{"trials":2191,"activeCount":97},[],{"trials":2193,"activeCount":97},[],{"trials":2195,"activeCount":97},[],{"trials":2197,"activeCount":97},[],{"trials":2199,"activeCount":97},[],{"trials":2201,"activeCount":97},[2202],{"nctId":2203,"briefTitle":2204,"status":542,"phases":2205,"primaryCompletion":2206,"completion":2206,"start":2207,"enrollment":19,"conditions":2208,"interventions":2212},"NCT03586089","Phenobarbital for Severe Acute Alcohol Withdrawal Syndrome",[89],"2023-07-17","2021-06-11",[2209,2210,2211],"Alcohol Withdrawal Delirium","Alcohol Withdrawal","Alcohol Withdrawal Seizures",[2188,2213],"Inactive placebo",{"intervention":2213,"totalTrials":93,"cells":2215},{"EARLY_PHASE1":2216,"PHASE1":2218,"PHASE2":2220,"PHASE3":2222,"PHASE4":2224,"NA":2226},{"trials":2217,"activeCount":97},[],{"trials":2219,"activeCount":97},[],{"trials":2221,"activeCount":97},[],{"trials":2223,"activeCount":97},[],{"trials":2225,"activeCount":97},[],{"trials":2227,"activeCount":97},[2228],{"nctId":2203,"briefTitle":2204,"status":542,"phases":2229,"primaryCompletion":2206,"completion":2206,"start":2207,"enrollment":19,"conditions":2230,"interventions":2231},[89],[2209,2210,2211],[2188,2213],{"intervention":2233,"totalTrials":93,"cells":2234},"Aspirin",{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2239,"PHASE3":2241,"PHASE4":2243,"NA":2245},{"trials":2236,"activeCount":97},[],{"trials":2238,"activeCount":97},[],{"trials":2240,"activeCount":97},[],{"trials":2242,"activeCount":97},[],{"trials":2244,"activeCount":97},[],{"trials":2246,"activeCount":97},[2247],{"nctId":2248,"briefTitle":2249,"status":566,"phases":2250,"primaryCompletion":2251,"completion":2251,"start":2252,"enrollment":2253,"conditions":2254,"interventions":2256},"NCT04269863","Personalizing Aspirin Therapy in Peripheral Arterial Disease Patients",[89],"2021-11","2020-11-01",150,[2255],"Peripheral Arterial Disease",[2233],{"intervention":2258,"totalTrials":93,"cells":2259},"1 unit of donated red blood cells",{"EARLY_PHASE1":2260,"PHASE1":2262,"PHASE2":2264,"PHASE3":2266,"PHASE4":2268,"NA":2270},{"trials":2261,"activeCount":97},[],{"trials":2263,"activeCount":97},[],{"trials":2265,"activeCount":97},[],{"trials":2267,"activeCount":97},[],{"trials":2269,"activeCount":97},[],{"trials":2271,"activeCount":97},[2272],{"nctId":2273,"briefTitle":2274,"status":554,"phases":2275,"primaryCompletion":825,"completion":1513,"start":2276,"enrollment":344,"conditions":2277,"interventions":2279},"NCT00470444","Transfusion Triggers in Cardiac Surgery",[89],"2006-12",[2278],"Cardiac Surgery",[2258,2258],{"intervention":2281,"totalTrials":93,"cells":2282},"Prednisolone acetate",{"EARLY_PHASE1":2283,"PHASE1":2285,"PHASE2":2287,"PHASE3":2289,"PHASE4":2291,"NA":2293},{"trials":2284,"activeCount":97},[],{"trials":2286,"activeCount":97},[],{"trials":2288,"activeCount":97},[],{"trials":2290,"activeCount":97},[],{"trials":2292,"activeCount":97},[],{"trials":2294,"activeCount":97},[2295],{"nctId":2296,"briefTitle":2297,"status":554,"phases":2298,"primaryCompletion":2299,"completion":2299,"start":558,"enrollment":2300,"conditions":2301,"interventions":2303},"NCT02412059","Topical Use of Corticosteroid to Prevent Epiretinal Membrane Following Retinal Tear",[89],"2016-01",200,[2302],"Epiretinal Membrane",[2281],{"intervention":2305,"totalTrials":93,"cells":2306},"Optimized medical therapy",{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2313,"PHASE4":2315,"NA":2317},{"trials":2308,"activeCount":97},[],{"trials":2310,"activeCount":97},[],{"trials":2312,"activeCount":97},[],{"trials":2314,"activeCount":97},[],{"trials":2316,"activeCount":97},[],{"trials":2318,"activeCount":97},[2319],{"nctId":2320,"briefTitle":2321,"status":542,"phases":2322,"primaryCompletion":2323,"completion":2323,"start":2001,"enrollment":2324,"conditions":2325,"interventions":2331},"NCT00524862","Standard Drug Therapy vs. Implanted Defibrillator for Primary Prevention of Sudden Cardiac Death",[89],"2011-04",5000,[2326,2327,2328,2329,2330],"Coronary Heart Disease","Congestive Heart Failure","Ventricular Dysfunction","Low Cardiac Output","Sudden Cardiac Death",[2305],{"intervention":2333,"totalTrials":93,"cells":2334},"Local anesthetic",{"EARLY_PHASE1":2335,"PHASE1":2337,"PHASE2":2339,"PHASE3":2341,"PHASE4":2343,"NA":2345},{"trials":2336,"activeCount":97},[],{"trials":2338,"activeCount":97},[],{"trials":2340,"activeCount":97},[],{"trials":2342,"activeCount":97},[],{"trials":2344,"activeCount":97},[],{"trials":2346,"activeCount":97},[2347],{"nctId":2348,"briefTitle":2349,"status":566,"phases":2350,"primaryCompletion":2351,"completion":2352,"start":2353,"enrollment":259,"conditions":2354,"interventions":2357},"NCT05286996","Cryoneurolysis for TKA - a Pilot Study",[89],"2023-10-01","2023-12-01","2022-12-01",[2355,2356],"Knee Pain Chronic","Osteoarthritis",[2333],{"intervention":2359,"totalTrials":93,"cells":2360},"Biomarker Testing",{"EARLY_PHASE1":2361,"PHASE1":2363,"PHASE2":2365,"PHASE3":2367,"PHASE4":2369,"NA":2371},{"trials":2362,"activeCount":97},[],{"trials":2364,"activeCount":97},[],{"trials":2366,"activeCount":97},[],{"trials":2368,"activeCount":97},[],{"trials":2370,"activeCount":97},[],{"trials":2372,"activeCount":97},[2373],{"nctId":2374,"briefTitle":2375,"status":566,"phases":2376,"primaryCompletion":2111,"completion":2111,"start":2377,"enrollment":344,"conditions":2378,"interventions":2380},"NCT01022086","Assessment of Cardiotoxicity by Cardiac Magnetic Resonance (CMR) in Breast Cancer Patients Receiving Trastuzumab",[],"2009-11",[2379],"Stage I-IV Breast Cancer (Neo-adjuvant, Adjuvant, Locally Advanced and Metastatic)",[2359],{"intervention":2382,"totalTrials":93,"cells":2383},"Meropenem",{"EARLY_PHASE1":2384,"PHASE1":2386,"PHASE2":2388,"PHASE3":2390,"PHASE4":2392,"NA":2394},{"trials":2385,"activeCount":97},[],{"trials":2387,"activeCount":97},[],{"trials":2389,"activeCount":97},[],{"trials":2391,"activeCount":97},[],{"trials":2393,"activeCount":97},[],{"trials":2395,"activeCount":97},[2396],{"nctId":2397,"briefTitle":2398,"status":542,"phases":2399,"primaryCompletion":1215,"completion":1215,"start":2400,"enrollment":290,"conditions":2401,"interventions":2403},"NCT01158937","Pharmacokinetic Study of Extended Infusion Meropenem in Adult Cystic Fibrosis Patients",[89],"2010-05",[2402],"Cystic Fibrosis Pulmonary Exacerbation",[2382]]